ReviewCurrent gastroenterology reports2026
Recent Endoscopic Technological Advancements in Crohn's Stricture Dilation.
Review in Current gastroenterology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCrohn’s disease (CD) often causes intestinal strictures that impair quality of life. Endoscopic balloon dilation (EBD) has long been the standard, but durability is limited. This review summarizes advances in endoscopic management, focusing on updates from 2019–2025. RECENT
findingsEBD achieves high technical success (90–95%) and short-term symptom relief (70–82%) but has recurrence rates up to 78% at two years. Endoscopic stricturotomy (ES) shows superior outcomes, with > 90% technical success, ~ 15% one-year recurrence, and > 70% five-year surgery-free survival. Hybrid ES + EBD approaches and novel stents—including fully covered self-expanding, biodegradable, and lumen-apposing devices—offer options for refractory lesions. Emerging imaging (EUS, elastography, hyperspectral imaging) and AI-assisted decision-making enhance stricture assessment, though data remain preliminary. Advances in endoscopy and adjunctive technologies are shifting Crohn’s stricture management toward more precise and durable, minimally invasive therapies. Ongoing trials, including HEIST, will help define optimal strategies.
Indexed as
Identifiers
41838301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.